Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases

Journal of Clinical Lipidology

Volumn 2, Issue 6, 2008, Pages 453-463

  Ming, Eileen E ^a,b   Davidson, Michael H ^c   Gandhi, Sanjay K ^a   Marotti, Marcelo ^a   Miles, Carolyn G ^a   Ke, Xiongkan ^a   McKenney, James M ^d  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d National Clinical Research Inc   (United States)

Author keywords

Adverse effects; Cardiovascular diseases; CYP3A4 protein; Cytochrome P450 enzyme system; Drug interactions; Human; Hydroxymethylglutaryl CoA reductase inhibitors; Hyperlipidemia; Polypharmacy

Indexed keywords

AMIODARONE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; APREPITANT; ATAZANAVIR; ATORVASTATIN; CHLORAMPHENICOL; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450 3A4; DANAZOL; DARUNAVIR; DEXTROPROPOXYPHENE; DILTIAZEM; EZETIMIBE PLUS SIMVASTATIN; FLUCONAZOLE; FLUINDOSTATIN; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; METRONIDAZOLE; MEVINOLIN; MIFEPRISTONE; OMEPRAZOLE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG; VERAPAMIL; ZAFIRLUKAST;

ADULT; ARTICLE; BILLING AND CLAIMS; CLINICAL PRACTICE; CONTINUING EDUCATION; CONTROLLED STUDY; DRUG LABELING; DRUG METABOLISM; DRUG UTILIZATION; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

EID: 57349130944     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.10.007     Document Type: Article

References (40)

1. Mackay J., and Mensah G.A. The atlas of heart disease and stroke (2004), WHO, Geneva, Switzerland
2. Castelli W.P., Garrison R.J., Wilson P.W., et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256 (1986) 2835-2838
3. Stamler J., Wentworth D., and Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?. Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256 (1986) 2823-2828
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
5. De Backer G., Ambrosioni E., Borch-Johnsen K., et al., Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 24 (2003) 1601-1610
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
7. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
8. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
9. LaRosa J.C., Grundy S.M., Waters D.D., et al., Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
10. Egger S.S., Rätz Bravo A.E., Hess L., Schlienger R.G., and Krähenbühl S. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 24 (2007) 429-440
11. Bottorff M.B. Statin safety and drug interactions: clinical implications. Am J Cardiol 97 suppl (2006) 27C-31C
12. Davidson M.H. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 5 (2006) 145-156
13. Leape L.L., Bates D.W., Cullen D.J., et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 274 (1995) 35-43
14. Heerey A., Barry M., Ryan M., and Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 169 (2000) 176-179
15. McDonnell P.J., and Jacobs M.R. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 36 (2002) 1331-1336
16. Etemad L. Statins and potentially interacting medications: a managed care perspective. Preventive medicine in managed care-statin drug interactions and implications for managed care. Am J Manag Care 4 suppl 2 (2004) S27-S29
17. Michalets E.L. Update: clinically significant cytochrome P-450 drug interactions. Pharmacother 18 (1998) 84-112
18. Rosenson R.S. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 1 (2003) 495-505
19. Omar M.A., Wilson J.P., and Cox T.S. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35 (2001) 1096-1107
20. Cziraky M.J., Willey V.J., McKenney J.M., et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 97 suppl (2006) 61C-68C
21. US Food and Drug Administration. Information for healthcare professionals: simvastatin (marketed as Zocor and generics), ezetimibe/simvastatin (marketed as Vytorin), niacin extended-release/simvastatin(marketed as Simcor), used with amiodarone (Cordarone, Pacerone). Last updated August 8, 2008. http://www.fda.gov/cder/drug/InfoSheets/HCP/simvastatin_amiodaroneHCP.htm Accessed August 28, 2008
22. Corsini A., Bellosta S., Baetta R., et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84 (1999) 413-428
23. Cooper K.J., Martin P.D., Dane A.L., et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 55 (2003) 94-99
24. Jacobson T.A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94 (2004) 1140-1146
25. Neuvonen P.J., Niemi M., and Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80 (2006) 565-581
26. Graham D.J., Staffa J.A., Shatin D., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 (2004) 2585-2590
27. Andrade S.E., Graham D.J., Staffa J.A., et al. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. J Clin Epidemiol 58 (2005) 171-174
28. Flockhart Drug Interaction. Last updated July 24, 2008. http://www.medicine.iupui.edu/flockhart/table.htm Accessed August 13, 2008
29. Worz C.R., and Bottorff M. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins. Expert Opin Pharmacother 2 (2001) 1119-1127
30. Hamilton R.A., Briceland L.L., and Andritz M.H. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 18 (1998) 1112-1120
31. Lazarou J., Pomeranz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279 (1998) 1200-1205
32. Chan M., Nicklason F., and Vial J.H. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J 31 (2001) 199-205
33. Morera T., Gervasini G., Carrillo J.A., and Benitez J. Using a computerized drug prescription screening system to trace drug interactions in an outpatient setting. Ann Pharmacother 38 (2004) 1301-1306
34. Piacentini N., Trifiró G., Tari M., Moretti S., Arcoraci V., and UVEC Group. Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol 61 (2005) 615-620
35. Einarson T.R., Metge C.J., Iskedjian M., and Mukherjee J. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther 24 (2002) 2126-2136
36. Molden E., Skovlund E., and Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Safety 31 (2008) 587-596
37. Flockhart Guidance for Industry. Drug interaction studies-study design, data analysis, and implications for dosing and labeling. September 2006. http://www.fda.gov/cder/guidance/6695dft.pdf Accessed August 13, 2008
38. Davidson M.H. Does differing metabolism by cytochrome P450 have clinical importance?. Curr Atheroscler Rep 2 (2000) 14-19
39. Grant R.W., O'Leary K.M., Weilburg J.B., Singer D.E., and Meigs J.B. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 164 (2004) 2343-2348
40. Mantel-Teeuwisse A.K., Klungel O.H., Schalekamp T., et al. Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol 60 (2005) 83-89